To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Kidney Cancer

Sumanta K. Pal, M.D.
Yervoy plus Opdivo is a good combination for many patients with kidney cancer, though some individuals should steer clear of the regimen.
Brielle Benyon
Certain factors – such as diastolic blood pressure and fasting insulin – were found to be associated with renal cell carcinoma.
Brielle Benyon
People who have experienced high exposures to gasoline might be at an increased risk for kidney cancer, according to recent research.
Brielle Benyon
Treatment side effects are typically manageable for patients with metastatic kidney cancer, but patients must have open communication with their health care team about them.
Jessica Skarzynski
A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.
Kristie L. Kahl
The phase 3 TIVO-3 trial – designed to evaluate the efficacy of Fotivda in patients with renal cell carcinoma – met its primary endpoint of improved progression-free survival.
Katie Kosko and Jessica Skarzynski
We've got a sneak peek at what’s inside our Fall 2018 issue.
Brielle Benyon
Checkpoint inhibitors are moving into the treatment realm of renal cell carcinoma; however, questions still remain.
Katie Kosko
Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.
Targeted drugs are controversial in early-stage kidney cancer, but play a more important role in treating advanced disease.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other